Dr. Glenn Matthew Chertow, MD

Dr. Chertow practices at Redwood City Medical Center in Redwood City, California, part of Kaiser Permanente.

Dr. Chertow's NPI, 1407823875, was assigned on March 3, 2006. Dr. Chertow graduated from Harvard Medical School in 1989. Dr. Chertow holds California license G84601.

Dr. Chertow's primary practice is Redwood City Medical Center, at 1100 Veterans Boulevard, Redwood City, CA 94063 in San Mateo County. The practice phone is (650) 299-2000.

Dr. Chertow's primary practice is Redwood City Medical Center in Redwood City, California, part of Kaiser Permanente. Dr. Chertow is also affiliated with Stanford Hospital at 300 Pasteur Drive. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Chertow to 5 more dialysis centers, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chertow practices, 7 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Chertow's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Chertow is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Chertow's licenses on file in 2 states: California and Massachusetts.

Dmand AI lists chronic kidney disease among the conditions Dr. Chertow treats.

CMS data shows 745 Medicare services from Dr. Chertow across 12 procedure codes in 2024, for 264 Medicare patients. Medicare paid $95,932 for them.

CMS counts 264 Medicare patients who saw Dr. Chertow in 2024. The largest group is 65 to 74, with 92 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 36% are also on Medicaid. Their average risk score is 5.30, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chertow's median patient age at 64, with 40% women.

In 2024, Dr. Chertow wrote 1,367 Medicare Part D claims for 176 patients. 69% of them were for generic drugs. CMS names the drug for 1,063 of them, across 30 drugs with 11 or more claims each, at $381,073 in total drug cost. In 2023, CMS named 1,025 claims across 23 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Chertow for performance year 2024, reported as part of a group. Dr. Chertow accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chertow as offering telehealth.

Dmand AI links 883 papers to Dr. Chertow, published from 2001 to 2025. 2021 was the busiest year, with 63. The most frequent topics are Renal Dialysis, Kidney Failure, Chronic and Renal Insufficiency, Chronic. Dr. Chertow has published most often in J Am Soc Nephrol. Dr. Chertow's most frequent co-authors are Wolfgang C. Winkelmayer, DSC, MD, Geoffrey Allan Block, MD and Lorien Sky Dalrymple, MD.

Dmand AI links Dr. Chertow to 2 clinical trials. Conditions studied include Kidney Failure, Chronic and Renal Insufficiency, Chronic.

CMS Open Payments shows 493 general payments to Dr. Chertow from 33 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 91% of the total. Outset Medical Inc paid the most, $681,926. It also lists 41 research payments totaling $113,902 from 2016 to 2025.

Dmand AI lists 5 awards for Dr. Chertow, most recently Regional Top Doctor in 2014.

Dr. Chertow graduated from Harvard Medical School in 1989. Dr. Chertow is a member of ACP and ASN.

Dr. Chertow is in network with 10 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.